Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

Exclusion Criteria

• •Local relapse alone after conservative treatment or contra-lateral tumor;
• •Patients with symptoms suggesting CNS involvement or leptomeningeal metastases;
• •Concomitant hormonal therapy for metastatic breast cancer;
• •Prior chemotherapy in the metastatic setting;
• •Patients previously treated with a vinca-alkaloid, capecitabine, gemcitabine or taxanes;
• •Prior severe and unexpected reaction to fluoropyrimidine therapy (with or without documented DPD deficiency) or known hypersensitivity to 5-fluorouracil.